Company intelligence / Profile preview
Angarus Therapeutics
Sunnyvale, California, United Statesangarustx.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Preclinical
01
Overview
Angarus Therapeutics has developed potent and selective small molecule inhibitors of ENPP1 and other ectonucleotidases that modulate tumor immune activity. These agents have shown preclinical efficacy in halting tumor growth and preventing metastasis, both as monotherapies and in combination with checkpoint inhibitors or radiation. The company’s programs are currently at the preclinical stage.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Angarus Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Angarus Therapeutics.